Gland Pharma stock volatile after announcing Q4 results, dividend; Details

Q: How long will it take to read this news story?

The story "Gland Pharma stock volatile after announcing Q4 results, dividend; Details" has 438 words across 19 sentences, which will take approximately 2 - 4 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Gland Pharma stock volatile after announcing Q4 results, dividend; Details" was covered 14 hours ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 275 news stories per day. It's most recent story was published 2 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #28885695</li><li>URL: https://inconstantly.beamstart.com/news/gland-pharma-stock-volatile-after-17478032676752</li></ul>

Business Standard Logo Business Standard 14h ago

Gland Pharma stock volatile after announcing Q4 results, dividend; Details - Business Standard

Quick Summary:

The market capitalisation of the company stood at ₹25,669.05 crore.

Its Earnings before interest, tax, depreciation, and amortisation (Ebitda) stood at ₹347.5 crore as compared to ₹358.7 crore a year ago.

The company launched four new molecules, including Latanoprost, Midazolam Bags RTU, Dexamethasone, and Vancomycin (New Strengths), which were launched in Q4 FY25, contributing to 31 cumulative launches in FY25.